Our products are researched and developed using a customer insights and market-led approach.

We use intelligence, data and analysis to support healthcare systems by tracking emerging threats, enabling us to be in a position to offer healthcare professionals, governments, individuals and organisations exactly what they need when it’s needed most.

We are informed by expert input from healthcare professionals and scientists as well as global surveillance systems. By identifying needs and trends early we can allocate resources ensuring we have reliable solutions to meet expected demand.

This approach underpins our commitment to being a ‘global first responder’ in the fight against infectious diseases and our agility has allowed us to bring this offering to life.

Novacyt will continue to invest in R&D in order to deliver new products in

  • Respiratory
  • Gastrointestinal
  • Transplant
  • Insect-borne diseases

We convene scientific and therapeutic advisory boards on international and domestic levels. Together with our surveillance mechanisms, these will assist the business with scientific guidance to direct our future innovations.

Future interests

We are also considering additional unmet needs in infectious diseases including sexually transmitted infections (STI), urinary tract infections (UTI), hospital acquired infections, meningitis/encephalitis and sepsis.

If you would like to explore collaborating with Novacyt in any of these areas please visit our Business Development page.

Knowledge Hub

Paris, France and Camberley, UK – 28 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of its research-use-only (RUO) polymerase......

Paris, France and Camberley, UK – 21 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s Annual General Meeting (AGM),......

Paris, France and Camberley, UK – 16 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with......

Paris, France and Camberley, UK – 13 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, will be holding its annual general meeting (AGM)......

Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s Annual Report and Accounts (“Annual Report”) for the year ended 31 December 2021 has......

Winter 2021/2022 could become the most challenging in decades for respiratory healthcare. There are many unknowns, such as the potential impact of circulating influenza or the trajectory of new COVID-19......

A multi-layered approach comprising vaccines, testing, lockdowns where necessary and medication will be essential for the foreseeable future in combatting COVID-19 – described as an “extraordinarily transmissible virus,” during the......

SARS-CoV-2 Mutations – Cause for Concern? The accumulation of genetic mutations is a normal part of viral evolution. Mutations change the sequence of the viral genome, creating different ‘variants.’ While......

SARS-CoV-2 Mutations – Cause for Concern? The accumulation of genetic mutations is a normal part of viral evolution. Mutations change the sequence of the viral genome, creating different ‘variants.’ While......

Learn more about our range of COVID-19 solutions and how they could help with your diagnostic needs. As we enter 2021, we also move into a new phase of the......

Despite the introduction of protective measures, the COVID-19 pandemic has continued to take hold across the world. The latest data from the World Health Organisation indicates that over 40 million......

Welcome back to the latest blog! As we edge closer to the winter season. This year will be a pivotal time for testing compared to previous years. Each year during......

    We are proud to have launched exsig™ a family of extraction workflow products tailored to suit your requirements in testing.  exsig™ is a product range like no other consisting of various......

Welcome to our latest blog! There have been many changes since our last blog, worldwide and within the company, our strong commitment to support testing remains.  Since our last update,......

In this blog, we take a look at technical design problems with primer/probes if not designed to the standard required. The design process is a pivotal part of the process......

What is Listeria? Listeria monocytogenes (genus listeria) is a bacterium illness that causes listeriosis. Listeria can be found in unpasteurised milk, dairy products, soft cheeses (camembert or brie) and chilled ready to......

Extension of contract continues multi-year assay design and development program Paris, France and Camberley, UK – 8 April 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in......

Completion of substantial q16 molecular diagnostics order expands clinical diagnostic reach in fast growing Chinese market Paris, France and Camberley, UK – 6th December 2018 – Novacyt (EURONEXT GROWTH: ALNOV;......

US partnership to facilitate the design and optimisation for customised microarray assays Paris, France and Camberley, UK – 13 September 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international......

Our webinar series on diagnostics and infectious diseases can be viewed here. Hear expert views on COVID-19 and other issues in infectious diseases.